Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 400 microgram - tablet, film coated - excipient ingredients: hyprolose; hypromellose; carnauba wax; magnesium stearate; mannitol; maize starch; propylene glycol; titanium dioxide; iron oxide red - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - gabapentin - oral capsule - 400mg

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - gabapentin - oral capsule - 400mg

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

medreich plc - gabapentin - oral capsule - 400mg

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - imatinib mesilate 477.88mg equivalent to imatinib 400 mg;   - capsule - 400 mg - active: imatinib mesilate 477.88mg equivalent to imatinib 400 mg   excipient: crospovidone gelatin iron oxide black iron oxide red iron oxide yellow lactose monohydrate magnesium stearate titanium dioxide - treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive chronic myeloid leukaemia (ph+cml). treatment of adult and paediatic patients with ph+cml in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

viatris limited - metronidazole 400mg;  ; metronidazole 400mg - tablet - 400 mg - active: metronidazole 400mg   excipient: maize starch dried lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone quinoline yellow sodium starch glycolate active: metronidazole 400mg excipient: maize starch 5% lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone quinoline yellow sodium starch glycolate - metronidazole is indicated in the prophylaxis and treatment of infections in which anaerobic bacteria have been identified or are suspected to be the cause. metronidazole is active against a wide range of pathogenic micro-organisms notably species of bacteroides, fusobacteria, clostridia, eubacteria, anaerobic cocci and gardnerella vaginalis. it is also active against trichomonas, entamoeba histolytica, giardia lamblia and balantidium coli. metronidazole is indicated in adults and children for the following indications: 1. the prevention of postoperative infections due to anaerobic bacteria, particularly species of bacteroides and anaerobic streptococci. 2.the treatment of septicaemia, bacteraemia, peritonitis, brain abcess, necrotising pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis, and post operative wound infections from which pathogenic anaerobes have been isolated. 3. urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male. 4. bacterial vaginosis (also known as non-specific vaginitis, anaerobic vaginosis or gardnerella vaginitis). 5. all forms of amoebiasis (intestinal and extra-intestinal disease and that of symptomless cyst passers). 6. giardiasis. 7. acute ulcerative gingivitis. 8. anaerobically infected leg ulcers and pressure sores. 9. acute dental infections due to anaerobic organisms (e.g. acute pericoronitis and acute apical infections).

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - imatinib mesilate, quantity: 477.88 mg (equivalent: imatinib, qty 400 mg) - capsule, hard - excipient ingredients: purified water; titanium dioxide; sodium lauryl sulfate; gelatin; sodium stearylfumarate; crospovidone; iron oxide yellow; iron oxide black; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia - indicated for the: ,? treatment of patients with chronic myeloid leukaemia (cml) ,? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy,? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ,? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ,? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ,? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ,? adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp). ? treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ? adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials)

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

lloyds pharmacy ltd - ibuprofen - oral tablet - 400mg

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

the boots company plc - ibuprofen - oral tablet - 400mg

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - gabapentin, quantity: 400 mg - capsule, hard - excipient ingredients: lactose monohydrate; maize starch; purified talc; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; indigo carmine; ethanol; butan-1-ol; shellac; methanol - neurontin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children aged 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. neurontin is indicated for the treatment of neuropathic pain